Clinicopathological and molecular predictors of [ < sup > 18 < /sup > F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial

CONCLUSIONS: These results highlight the clinical, biological, and metabolic heterogeneity of HER2+ breast cancer, which may facilitate the selection of HER2+ EBC patients likely to benefit from [18F]FDG-PET imaging as a tool to guide therapy.TRIAL REGISTRATION: Clinicaltrials.gov; NCT03161353; registration date: May 15, 2017.PMID:38587643 | DOI:10.1007/s00259-024-06683-0

Source: Molecular Medicine - April 8, 2024 Category: Molecular Biology Authors: Antonio Llombart-Cussac Aleix Prat Jos é Manuel Pérez-García Jos é Mateos Tom ás Pascual Santiago Escriv à-de-Romani Agostina Stradella Manuel Ruiz-Borrego Bego ña Bermejo de Las Heras Marleen Keyaerts Patricia Galvan Fara Bras ó-Maristany Juan Jo Source Type: research